Logo image of BDRX

BIODEXA PHARMACEUTICALS-ADR (BDRX) Stock Fundamental Analysis

NASDAQ:BDRX - Nasdaq - US59564R8079 - ADR - Currency: USD

4.8  -0.14 (-2.83%)

Premarket: 4.77 -0.03 (-0.63%)

Fundamental Rating

2

Overall BDRX gets a fundamental rating of 2 out of 10. We evaluated BDRX against 572 industry peers in the Biotechnology industry. Both the profitability and financial health of BDRX have multiple concerns. BDRX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

BDRX had negative earnings in the past year.
BDRX had a negative operating cash flow in the past year.
BDRX had negative earnings in each of the past 5 years.
In the past 5 years BDRX always reported negative operating cash flow.
BDRX Yearly Net Income VS EBIT VS OCF VS FCFBDRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -5M -10M -15M -20M

1.2 Ratios

BDRX has a Return On Assets (-48.82%) which is in line with its industry peers.
BDRX has a Return On Equity (-78.14%) which is in line with its industry peers.
Industry RankSector Rank
ROA -48.82%
ROE -78.14%
ROIC N/A
ROA(3y)-82.67%
ROA(5y)-101.33%
ROE(3y)-148.56%
ROE(5y)-165.51%
ROIC(3y)N/A
ROIC(5y)N/A
BDRX Yearly ROA, ROE, ROICBDRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

BDRX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BDRX Yearly Profit, Operating, Gross MarginsBDRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

BDRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BDRX has been increased compared to 1 year ago.
Compared to 1 year ago, BDRX has an improved debt to assets ratio.
BDRX Yearly Shares OutstandingBDRX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2K 4K 6K 8K
BDRX Yearly Total Debt VS Total AssetsBDRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -10.38, we must say that BDRX is in the distress zone and has some risk of bankruptcy.
BDRX has a Altman-Z score of -10.38. This is in the lower half of the industry: BDRX underperforms 75.22% of its industry peers.
BDRX has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
BDRX has a Debt to Equity ratio (0.02) which is in line with its industry peers.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z -10.38
ROIC/WACCN/A
WACC8.2%
BDRX Yearly LT Debt VS Equity VS FCFBDRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M 15M

2.3 Liquidity

A Current Ratio of 2.16 indicates that BDRX has no problem at all paying its short term obligations.
BDRX's Current ratio of 2.16 is on the low side compared to the rest of the industry. BDRX is outperformed by 74.69% of its industry peers.
A Quick Ratio of 2.16 indicates that BDRX has no problem at all paying its short term obligations.
BDRX's Quick ratio of 2.16 is on the low side compared to the rest of the industry. BDRX is outperformed by 73.27% of its industry peers.
Industry RankSector Rank
Current Ratio 2.16
Quick Ratio 2.16
BDRX Yearly Current Assets VS Current LiabilitesBDRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

2

3. Growth

3.1 Past

BDRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.74%, which is quite impressive.
The Revenue for BDRX has decreased by -84.31% in the past year. This is quite bad
The Revenue has been growing slightly by 3.56% on average over the past years.
EPS 1Y (TTM)98.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.19%
Revenue 1Y (TTM)-84.31%
Revenue growth 3Y3.56%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, BDRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.16% on average per year.
BDRX is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -73.72% yearly.
EPS Next Y80.32%
EPS Next 2Y36.71%
EPS Next 3Y22.81%
EPS Next 5Y17.17%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-73.72%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BDRX Yearly Revenue VS EstimatesBDRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2M 4M 6M 8M
BDRX Yearly EPS VS EstimatesBDRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -20 -40 -60 -80

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

BDRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BDRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BDRX Price Earnings VS Forward Price EarningsBDRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BDRX Per share dataBDRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60

4.3 Compensation for Growth

A more expensive valuation may be justified as BDRX's earnings are expected to grow with 22.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.71%
EPS Next 3Y22.81%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BDRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIODEXA PHARMACEUTICALS-ADR

NASDAQ:BDRX (2/12/2025, 8:00:01 PM)

Premarket: 4.77 -0.03 (-0.63%)

4.8

-0.14 (-2.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-12 2023-09-12
Earnings (Next)N/A N/A
Inst Owners19.68%
Inst Owner Change-12.89%
Ins Owners4.19%
Ins Owner ChangeN/A
Market Cap3.21M
Analysts85.71
Price Target204 (4150%)
Short Float %1.09%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 31.07
P/FCF N/A
P/OCF N/A
P/B 0.3
P/tB 0.95
EV/EBITDA N/A
EPS(TTM)-74.06
EYN/A
EPS(NY)-3.25
Fwd EYN/A
FCF(TTM)-16.49
FCFYN/A
OCF(TTM)-14.43
OCFYN/A
SpS0.15
BVpS16.24
TBVpS5.06
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -48.82%
ROE -78.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-82.67%
ROA(5y)-101.33%
ROE(3y)-148.56%
ROE(5y)-165.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 402.54%
Cap/Sales 1338.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.16
Quick Ratio 2.16
Altman-Z -10.38
F-Score2
WACC8.2%
ROIC/WACCN/A
Cap/Depr(3y)63.47%
Cap/Depr(5y)46.48%
Cap/Sales(3y)44.42%
Cap/Sales(5y)48.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)98.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.19%
EPS Next Y80.32%
EPS Next 2Y36.71%
EPS Next 3Y22.81%
EPS Next 5Y17.17%
Revenue 1Y (TTM)-84.31%
Revenue growth 3Y3.56%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-73.72%
EBIT growth 1Y14.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-34.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.39%
OCF growth 3YN/A
OCF growth 5YN/A